While we look forward to seeing efficacy confirmation in the interim analysis of related ongoing products, such as TK-007 (CD19-28-ζ CAR/IL-15 UCB NK cells) or FT576 (iPSC-derived BCMA CAR-NK in MM), these early results suggest similar high-quality responses using CAR-NK cells as compared to CAR-T cells. This evidence concerns the gene IL15 and Miyoshi myopathy.